Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo

Vitiligo Clinical Trial

Official title:

Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02506101
• Other study ID #: IRB00052103
• Status: Terminated
• Phase: N/A
• First received: July 21, 2015
• Last updated: March 9, 2018
• Start date: July 2015
• Est. completion date: October 4, 2016

Study information

• Verified date: March 2018
• Source: Johns Hopkins University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to assess the effectiveness and safety of narrowband-ultraviolet B (NB-UVB) treatment in adult subjects with vitiligo.

Description:

Vitiligo is a chronic acquired cutaneous disease of pigmentation that affects patients' quality of life across all degrees of involvement and severity. Phototherapy is a clinically indicated treatment for skin lesions. Treatments are usually administered in an outpatient setting, typically three times per week. This is a proof-of-concept study as there are few well-designed prospective clinical studies showing the efficacy of NB-UVB phototherapy in the treatment of vitiligo in terms of repigmentation and quality of life. The following are the proposed objectives of this study:

1. NB-UVB phototherapy improves vitiligo with at least 50% repigmentation compared to no treatment on affected areas of the trunk and extremities over 24 weeks.

2. NB-UVB phototherapy leads to improvement in quality of life as measured by standardized quality of life metrics (DLQI and Skindex-29) over 24 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 2
• Est. completion date: October 4, 2016
• Est. primary completion date: October 4, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults 18 years or older with bilateral symmetrical vitiligo lesions, in general good health as determined by the Principal Investigator by medical history and physical exam.

• Able to understand consent procedure

• Able to comply with protocol activities

• If a woman, before entry she must be:

1. postmenopausal, defined as 45 years of age with amenorrhea for at least 18 months, or >45 years of age with amenorrhea for at least 6 months and a serum follicule stimulating hormone (FSH) level >40 IU/mL, or surgically postmenopausal (bilateral oophorectomy), or

2. surgically sterile (have had a hysterectomy or tubal ligation or otherwise be incapable of pregnancy), or

3. If heterosexually active and of childbearing potential, practicing a highly effective method of birth control, (examples include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragms, or cervical cap, with spermicidal foam, cream, or gel), or male partner sterilization consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials, for the duration of their participation in the study, or

4. Not heterosexually active

Exclusion Criteria:

• Patients less than 18 years old

• Patients not able to understand consent procedure

• Patients unable to comply with protocol activities

• Patients that do not have bilateral symmetrical vitiligo lesions

• Non-English speakers: the study assessments/questionnaires/evaluations are not scientifically validated in languages other than English. Given the lack of translators in over 50% of patient encounters in the dermatology clinic and the interpreters' limited time commitments when one does show up, it is impossible to safely enroll or follow patients who do not speak English. Phone translators are impossible given that we have written consent forms, which often exceed 10 pages in length.

• Patients with a photosensitive disorder or on a medication which has been demonstrated in these patients to cause photosensitivity

• Patients receiving concomitant phototherapy to test sites

• Patient receiving topical medication to test sites within 2 weeks of study initiation

• Patient receiving oral medications for vitiligo within 4 weeks prior to study initiation

• Receipt of an investigation agent within the past 4 weeks (or within 5 half lives) prior to study initiation

• Systemic corticosteroid therapy within the past month Concurrent use of drugs listed in Appendix C.

Related Conditions & MeSH terms

• Dyschromia
• Pigmentation
• Vitiligo

Intervention

Device:
• narrow-band ultraviolet B phototherapy
There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.

Locations

Country	Name	City	State
United States	Johns Hopkins Dept. of Dermatology	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Response Stability Index		24 weeks
Other	Number of Participants With Histological Change in Tissue Samples		24 weeks
Primary	Vitiligo Area Scoring Index (VASI)	VASI scores of treated versus untreated symmetrical body sites.The percentage of vitiligo involvement is calculated in terms of hand units. One hand unit is approximately equivalent to 1% of the total body surface area. The degree of pigmentation is estimated to the nearest of one of the following percentages: 100% - complete depigmentation, no pigment is present; 90% - specks of pigment present; 75% - depigmented area exceeds the pigmented area; 50% - pigmented and depigmented areas are equal; 25% - pigmented area exceeds depigmented area; and 10% - only specks of depigmentation present. The VASI for each body region is determined by the product of the area of vitiligo in hand units and the extent of depigmentation within each hand unit measured patch. Total body VASI = S All body sites [Hand Units] ´ [Residual depigmentation].	24 weeks
Secondary	Dermatology Life Quality Index (DLQI)	Quality of life assessment	24 weeks
Secondary	Skindex-29 Questionnaire	Quality of life assessment	24 weeks